Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2025)

Benitec Biopharma has disclosed Accumulated Expenses across 7 years of filings, most recently posting $483000.0 for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $483000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $483000.0 (changed N/A YoY), and the FY2025 annual result was $426000.0, down 10.32% from the prior year.
• Accumulated Expenses came in at $483000.0 for Q4 2025 at Benitec Biopharma, up from $463000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $523000.0 in Q4 2023 to a low of $231000.0 in Q1 2021.
• The 5-year median for Accumulated Expenses is $427500.0 (2023), against an average of $411666.7.
• Across the five-year window, Accumulated Expenses surged 54.55% in 2022 and declined 10.32% in 2025, its largest moves.
• Benitec Biopharma's Accumulated Expenses stood at $321000.0 in 2021, then climbed by 23.36% to $396000.0 in 2022, then surged by 32.07% to $523000.0 in 2023, then dropped by 5.35% to $495000.0 in 2024, then declined by 2.42% to $483000.0 in 2025.
• The last three Accumulated Expenses figures came in at $483000.0 (Q4 2025), $463000.0 (Q3 2025), and $426000.0 (Q2 2025), per Business Quant data.